Andrei V. Gudkov
Affiliations: | 1990-2001 | Molecular Genetics | University of Illinois at Chicago, Chicago, IL, United States |
| 2001-2007 | Molecular Biology and Professor of Biochemistry | Case Western Reserve University, Cleveland Heights, OH, United States | |
| 2007- | Roswell Park . Cellular and Molecular Biology | State University of New York, Buffalo, Buffalo, NY, United States |
Area:
Molecular Biology, General Biology, Immunology, OncologyWebsite:
https://www.roswellpark.org/andrei-gudkovGoogle:
"Andrei V. Gudkov"Bio:
http://www.cbiolabs.com/andrei-gudkov-ph-d-d-sci/
https://www.researchgate.net/profile/Andrei_Gudkov
https://scholar.google.com/citations?user=gAT9SJwAAAAJ&hl=en
Children
Sign in to add trainee| Andrei Thomas-Tikhonenko | grad student | ||
| Alexander D. Boiko | grad student | 2005 | University of Illinois at Chicago, Health Sciences Center (Neurotree) |
| Yekaterina I. Leonova | grad student | 2012 | SUNY Buffalo |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Novototskaya-Vlasova KA, Neznanov NS, Molodtsov I, et al. (2022) Inflammatory response to retrotransposons drives tumor drug resistance that can be prevented by reverse transcriptase inhibitors. Proceedings of the National Academy of Sciences of the United States of America. 119: e2213146119 |
| Antoch MP, Wrobel M, Gillard B, et al. (2020) Superior cancer preventive efficacy of low versus high dose of mTOR inhibitor in a mouse model of prostate cancer. Oncotarget. 11: 1373-1387 |
| Eremina NV, Kazey VI, Mishugin SV, et al. (2020) First-in-human study of anticancer immunotherapy drug candidate mobilan: safety, pharmacokinetics and pharmacodynamics in prostate cancer patients. Oncotarget. 11: 1273-1288 |
| Haderski GJ, Kandar BM, Brackett CM, et al. (2020) TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects. Plos One. 15: e0227940 |
| Korotchkina L, Kazyulkin D, Komarov PG, et al. (2020) OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis. Leukemia |
| Sarantopoulos J, Mahalingam D, Sharma N, et al. (2020) Results of a completed phase I trial of CBL0137 administered intravenously (IV) to patients (Pts) with advanced solid tumors. Journal of Clinical Oncology. 38: 3583-3583 |
| Haber M, Gamble L, Xiao L, et al. (2020) Abstract IA13: Molecular targeted therapies and precision medicine for children with neuroblastoma and other refractory malignancies Cancer Research. 80 |
| Leonova K, Safina A, Gudkov AV, et al. (2020) Abstract 4496: Induction of immunogenicity in tumor cells by small molecule drugs that destabilize nucleosomes Cancer Research. 80: 4496-4496 |
| Somers K, Evans K, Cheung L, et al. (2019) Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia. Leukemia |
| Kirsanov KI, Fetisov T, Lesovaya EA, et al. (2019) Prevention of colorectal carcinogenesis by DNA binding small molecule curaxin CBL0137 involves suppression of Wnt signaling. Cancer Prevention Research (Philadelphia, Pa.) |